Metastatic Castrate Resistant Prostate Cancer clinical trials

Explore recruiting metastatic castrate resistant prostate cancer clinical trials.

Recruiting metastatic castrate resistant prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Castrate Resistant Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

Sweden, Netherlands, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Italy, Germany, Poland, France, Denmark, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Spain, Poland, Netherlands, Italy, Germany, Ireland +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of androgen receptor pathway inhibitor (ARPI) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of ARPI

Italy, Poland, Lithuania, Austria, Hungary, France +4 more

Therapeutic use (Phase IV) EU CTIS Study details

PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

Spain, Slovakia, Czechia, Sweden, Belgium, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metastatic Castrate Resistant Prostate Cancer trials by city

Metastatic Castrate Resistant Prostate Cancer in Toronto Metastatic Castrate Resistant Prostate Cancer in Vancouver Metastatic Castrate Resistant Prostate Cancer in Montreal Metastatic Castrate Resistant Prostate Cancer in Calgary Metastatic Castrate Resistant Prostate Cancer in Edmonton Metastatic Castrate Resistant Prostate Cancer in Ottawa Metastatic Castrate Resistant Prostate Cancer in Winnipeg Metastatic Castrate Resistant Prostate Cancer in Quebec City Metastatic Castrate Resistant Prostate Cancer in Hamilton Metastatic Castrate Resistant Prostate Cancer in Kitchener Metastatic Castrate Resistant Prostate Cancer in London Metastatic Castrate Resistant Prostate Cancer in Halifax Metastatic Castrate Resistant Prostate Cancer in New York Metastatic Castrate Resistant Prostate Cancer in Los Angeles Metastatic Castrate Resistant Prostate Cancer in Chicago Metastatic Castrate Resistant Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease